This work presents a thorough investigation of the interaction of the novel synthetic pyrrolidinone analog 28 MMK3 with the model membrane system of dipalmitoylphosphatidylcholine (DPPC) and the receptor active 29 site. MMK3 has been designed to exert antihypertensive activity by functioning as an antagonist of the 30 angiotensin II receptor of subtype 1 (AT 1 ). Its low energy conformers were characterized by 2D rotating-frame 31 Overhauser effect spectroscopy (ROESY) in combination with molecular dynamics (MD) simulations. Docking 32 study of MMK3 shows that it fits to the AT 1 receptor as SARTANs, however, its biological activity appears to be 33 lower. Thus, differential scanning calorimetry (DSC), Raman spectroscopy and small angle X-ray scattering 34 (SAXS) experiments on the interaction of MMK3 with DPPC bilayers were carried out and results demonstrate 35 that the drug is well incorporated into the membrane leaflets and furthermore causes partial bilayer 36 interdigitation, although less effective than SARTANs. Thus, it appears that the nature of the bilayer matrix and 37 the stereoelectronic active site requirements of the receptor are responsible for the low bioactivity of MMK3.
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Introduction
44
The renin angiotensin system (RAS) constitutes the major system 45 that regulates blood pressure. Therefore, it is the main target in the 46 drug design for developing novel synthetic antihypertensive drugs.
The first rationale behind the synthesis of novel angiotensin analogs 48 was to block the formation of vasoconstrictive hormone angiotensin II 49 (Ang II). Renin and angiotensin converting enzymes are responsible 50 for transforming in the body angiotensinogen to angiotensin I (Ang I) 51 and subsequently to Ang II. The blocking of angiotensin converting 52 enzyme was crowned with success and the market experienced 53 captopril and its congeners as beneficial molecules in blood 54 regulation. However, their side effects of dry mouth and angioedema 55 precluded them from being the ideal drugs for hypertension. Recently, 56 the synthetic molecule aliskiren^entered the market with trade name 57 Tekturna (Novartis) and is the only available inhibitor from the renin 58 inhibitor class [1] . 59 The second class of synthetic molecules aims to^block^Ang II at the 60 AT 1 receptor [2] . The first peptide analogs synthesized for this purpose, 61 although not successful, provided molecular models for further rational 62 drug design. To comprehend the stereoelectronic requirements for 63 receptor binding, the stereochemical features of Ang II and its peptide 64 antagonists sarmesin and sarilesin were explored [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . These 65 synthetic peptide analogues and other non-peptide AT 1 antagonists
66
(commercially available and novel compounds) are designed to mimic 67 the C-terminal part of Ang II. In this regard, losartan was the first 68 successful peptidomimetic analog to be marketed. Furthermore, 69 angiotensin receptor blockers (ARBs) have been developed to produce 70 a more complete blockade of the action of angiotensin II as compared to 71 other drug classes as well as decrease of their side effects [13] [14] [15] [16] [17] [18] .
72
Based on the molecular characterization of these antagonists, a However, MMK1 did not show the desired biological properties as 78 the in vitro and in vivo studies demonstrated [19] . For this purpose,
79
we proceeded with the synthesis of a derivative of MMK1, the (5S)-1-
named MMK3 (Fig. 1 by the ROESY spectrum were selected. The coordinate of the MMK3 ligand was submitted to PRODRG [41] 202 algorithm to obtain Gromacs topologies. Corporation, Northampton, MA) was used for the plots. . For the measurements, the 260 sample was transferred in a 1.5 mm capillary and measured at 25 and 
329
The best-docked complex among the three lowest energy Table 3 t3:1 Values of dihedral angles (defined in Fig. 1 A representative snapshot of the MD simulations is shown in the showed to be stable. mol for x =^0.01 to 0.20 and it is above that of DPPC (7.^4 kcal/mol).
373
However, the total ΔΗ remains below the total enthalpy of the pure 374 DPPC bilayers (8.^5 kcal/mol). As we will outline later this enthalpy 375 increase indicates a partial interdigitation of the alkyl chains. were recorded in a range of 500-^3500 cm to gauche isomerizations.
397
The methylene C-^H stretching^mode region 2800-^3100 cm Second, at 714 cm −1 corresponding to C-^N stretch vibration, a shift to water system (Table 5 ). In the fluid lamellar phase at 50°C the system are very similar to those found in pure DPPC [63] [64] [65] [66] [67] (Table 5) .
446
However, the fitting results show that the bilayer thickness is clearly 447 reduced (about^−4 Å) (Fig. 8D) . lowering, decrease of cooperativity and slight increase of enthalpy (Fig. 5) . neighboring lipid molecules to interdigitate partially. We note that 501 the scheme bases on experimental X-ray data, i.e. the decomposition Table 5 . (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) In conclusion, we showed that MMK3'^s observed lower bioactivity active solute leaves its special fingerprint [74] , and it will be of great 548 importance for future rational drug design to understand not only 549 direct drug action at the active site, but also to understand specific 550 drug to bilayer interactions to foresee at least qualitatively the 551 consequences for drug efficiency. 
